NUPROBE USA, INC.
Medtech · Private
qPCR-based SNP profiling assays for detecting cell line contamination using blocker displacement amplification technology
- Grants
- $2.2M
- 5 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 11
- 0 granted · 11 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Rapid, Simple and Cost-Effective Detection of Human Cell Line Contamination | $749,300 | |
| Federal grant | Department of Health and Human Services · Phase I · Allele selective enrichment for targeted profiling of rare cancer mutations via low-depth sequencing | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · A highly multiplexed convection flow RT-qPCR assay for rapid and | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid, Simple and Cost-Effective Detection of Human Cell Line Contamination | $716,643 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid, Simple and Cost-Effective Detection of Human Cell Line Contamination | $254,960 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2072 | Double Helix Optics Inc | — | — |
| 2073 | DURAMETRIX LLC | — | — |
| 2074 | ClaimDetect LLC | — | — |
| 2075 | NUPROBE USA, INC. | — | — |
| 2076 | STETH X MICROSYSTEMS, INC. | — | — |
| 2077 | APK ADVANCED MEDICAL TECHNOLOGIES, INC. | — | — |
| 2078 | PIERSON BRAIN IMAGE ANALYSIS | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods And Compositions For Sequencing And Fusion Detection Using Randomer Reverse Primersapplication
- High Sensitivity Detection Of Microsatellite Loci By Blocker Displacement Amplification With Multiple Blockers And Its Use In Microsatellite Instability Detectionapplication
- Expression-weighted Tumor Mutational Burden As An Oncology Biomarkerapplication
- Methods And Compositions For Sequencing And Fusion Detection Using Randomer Reverse Primersapplication
- Rna Quantitative Amplicon Sequencing For Gene Expression Quantitationapplication
- High Sensitivity Detection Of Microsatellite Loci By Blocker Displacement Amplification With Multiple Blockers And Its Use In Microsatellite Instability Detectionapplication
- Universal Probes For Amplification And Detection Of Nucleic Acidsapplication
- Expression-weighted Tumor Mutational Burden As An Oncology Biomarkerapplication
- Rna Quantitative Amplicon Sequencing For Gene Expression Quantitationapplication
- High Sensitivity Detection Of Microsatellite Loci By Blocker Displacement Amplification With Multiple Blockers And Its Use In Microsatellite Instability Detectionapplication
- Universal Probes For Amplification And Detection Of Nucleic Acidsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.